Rationale, Design and Participants Baseline Characteristics of a Crossover Randomized Controlled Trial of the Effect of Replacing SSBs with NSBs versus Water on Glucose Tolerance, Gut Microbiome and Cardiometabolic Risk in Overweight or Obese Adult SSB Consumer: Strategies to Oppose SUGARS with Non-Nutritive Sweeteners or Water (STOP Sugars NOW) Trial and Ectopic Fat Sub-Study
Nutrients · 2023
DOI: 10.3390/nu15051238 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2023. Verfasst von Sabrina Ayoub-Charette und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada. Hauptthemen laut MEDLINE: Non-Nutritive Sweeteners, Sugar-Sweetened Beverages, Gastrointestinal Microbiome, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research, Province of Ontario, Ministry of Research and Innovation and Science.
Abstract (Originalsprache)
Background
Health authorities are near universal in their recommendation to replace sugar-sweetened beverages (SSBs) with water. Non-nutritive sweetened beverages (NSBs) are not as widely recommended as a replacement strategy due to a lack of established benefits and concerns they may induce glucose intolerance through changes in the gut microbiome. The STOP Sugars NOW trial aims to assess the effect of the substitution of NSBs (the “intended substitution”) versus water (the “standard of care substitution”) for SSBs on glucose tolerance and microbiota diversity. Design and Methods: The STOP Sugars NOW trial (NCT03543644) is a pragmatic, “head-to-head”, open-label, crossover, randomized controlled trial conducted in an outpatient setting. Participants were overweight or obese adults with a high waist circumference who regularly consumed ≥1 SSBs daily. Each participant completed three 4-week treatment phases (usual SSBs, matched NSBs, or water) in random order, which were separated by ≥4-week washout. Blocked randomization was performed centrally by computer with allocation concealment. Outcome assessment was blinded; however, blinding of participants and trial personnel was not possible. The two primary outcomes are oral glucose tolerance (incremental area under the curve) and gut microbiota beta-diversity (weighted UniFrac distance). Secondary outcomes include related markers of adiposity and glucose and insulin regulation. Adherence was assessed by objective biomarkers of added sugars and non-nutritive sweeteners and self-report intake. A subset of participants was included in an Ectopic Fat sub-study in which the primary outcome is intrahepatocellular lipid (IHCL) by 1H-MRS. Analyses will be according to the intention to treat principle. Baseline results: Recruitment began on 1 June 2018, and the last participant completed the trial on 15 October 2020. We screened 1086 participants, of whom 80 were enrolled and randomized in the main trial and 32 of these were enrolled and randomized in the Ectopic Fat sub-study. The participants were predominantly middle-aged (mean age 41.8 ± SD 13.0 y) and had obesity (BMI of 33.7 ± 6.8 kg/m2) with a near equal ratio of female: male (51%:49%). The average baseline SSB intake was 1.9 servings/day. SSBs were replaced with matched NSB brands, sweetened with either a blend of aspartame and acesulfame-potassium (95%) or sucralose (5%).
Conclusions
Baseline characteristics for both the main and Ectopic Fat sub-study meet our inclusion criteria and represent a group with overweight or obesity, with characteristics putting them at risk for type 2 diabetes. Findings will be published in peer-reviewed open-access medical journals and provide high-level evidence to inform clinical practice guidelines and public health policy for the use NSBs in sugars reduction strategies.
Trial registration
ClinicalTrials.gov identifier, NCT03543644.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
- Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, Toronto, ON M5C 2T2, Canada.
- Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
- Department of Chemical Engineering and Applied Chemistry, Faculty of Applied Science and Engineering, University of Toronto, Toronto, ON M5S 3E5, Canada.
- College of Dietitians of Ontario, Ontario, ON M2M 4J1, Canada.
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
ORCID-Profile: Sabrina Ayoub-Charette, Danielle Lee, Sonia Blanco Mejia, Laura Chiavaroli, Meaghan E Kavanagh, Amel Taibi, Yue-Tong Chen, D Dan Ramdath, Lawrence A Leiter, Elena M Comelli
Förderung
- CIHR
- Canadian Institutes of Health Research
- Province of Ontario, Ministry of Research and Innovation and Science
- Nutrition Trialist Research Fund at the University of Toronto
- The Canada Foundation for Innovation
- Ministry of Research, and Innovation’s Ontario Research Fund
- CIHR Canadian Graduate Scholarship Doctoral Award
- Loblaw Food as Medicine Graduate Award
Zitieren
APA
Ayoub-Charette, S., McGlynn, N. D., Lee, D., Khan, T. A., Blanco Mejia, S., Chiavaroli, L., Kavanagh, M. E., Seider, M., Taibi, A., Chen, C. T., Ahmed, A., Asbury, R., Erlich, M., Chen, Y. T., Malik, V. S., Bazinet, R. P., Ramdath, D. D., Logue, C., Hanley, A. J., …, & Sievenpiper, J. L. (2023). Rationale, Design and Participants Baseline Characteristics of a Crossover Randomized Controlled Trial of the Effect of Replacing SSBs with NSBs versus Water on Glucose Tolerance, Gut Microbiome and Cardiometabolic Risk in Overweight or Obese Adult SSB Consumer: Strategies to Oppose SUGARS with Non-Nutritive Sweeteners or Water (STOP Sugars NOW) Trial and Ectopic Fat Sub-Study. Nutrients. https://doi.org/10.3390/nu15051238
Vancouver
Ayoub-Charette S, McGlynn ND, Lee D, Khan TA, Blanco Mejia S, Chiavaroli L, et al. Rationale, Design and Participants Baseline Characteristics of a Crossover Randomized Controlled Trial of the Effect of Replacing SSBs with NSBs versus Water on Glucose Tolerance, Gut Microbiome and Cardiometabolic Risk in Overweight or Obese Adult SSB Consumer: Strategies to Oppose SUGARS with Non-Nutritive Sweeteners or Water (STOP Sugars NOW) Trial and Ectopic Fat Sub-Study. Nutrients. 2023. doi:10.3390/nu15051238
BibTeX
@article{AyoubCharette2023,
author = {Ayoub-Charette, Sabrina and McGlynn, Néma D and Lee, Danielle and Khan, Tauseef Ahmad and Blanco Mejia, Sonia and Chiavaroli, Laura and Kavanagh, Meaghan E and Seider, Maxine and Taibi, Amel and Chen, Chuck T and Ahmed, Amna and Asbury, Rachel and Erlich, Madeline and Chen, Yue-Tong and Malik, Vasanti S and Bazinet, Richard P and Ramdath, D Dan and Logue, Caomhan and Hanley, Anthony J and Kendall, Cyril W C and Leiter, Lawrence A and Comelli, Elena M and Sievenpiper, John L},
title = {Rationale, Design and Participants Baseline Characteristics of a Crossover Randomized Controlled Trial of the Effect of Replacing SSBs with NSBs versus Water on Glucose Tolerance, Gut Microbiome and Cardiometabolic Risk in Overweight or Obese Adult SSB Consumer: Strategies to Oppose SUGARS with Non-Nutritive Sweeteners or Water (STOP Sugars NOW) Trial and Ectopic Fat Sub-Study},
journal = {Nutrients},
year = {2023},
doi = {10.3390/nu15051238}
}
EUVIMED